Cancer Biotech Oasmia Hid Deals From Investors, Suit Says
Investors for Swedish cancer biotechnology firm Oasmia launched a proposed class action lawsuit in New York federal court Monday, alleging the company actively concealed a number of deals involving entities owned...To view the full article, register now.
Already a subscriber? Click here to view full article